Mycobacterial infections with Ruxolitinib: A retrospective pharmacovigilance review

Patients on Ruxolitinib may be predisposed to mycobacterial infections. This observational, retrospective pharmacovigilance study used the FDA adverse events reporting system to compare the number of patients that developed typical and atypical mycobacterial infections to all drugs in the system. Using the reporting odds ratio, there is an increased risk of developing Tuberculosis (ROR 9.2; 95% CI 7.5-11.4) and atypical mycobacterial infections (ROR 8.3; 95% CI 5.5-12.6) while on treatment with Ruxolitinib.

Source: Clinical Lymphoma, Myeloma and Leukemia - August 25, 2019 Category: Hematology Authors: Kartik Anand, Ethan A. Burns, Joe Ensor, Lawrence Rice, Sai Ravi Pingali Tags: Original Study Source Type: research